Status:
COMPLETED
Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Adenocarcinoma of Lung Stage IV
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in, Somatic
Eligibility:
All Genders
18+ years
Brief Summary
The recent discovery of oncogenic drivers has revolutionized the management of advanced lung cancer by development of tyrosine kinase inhibitors targeted therapies. Prevalence of daily tobacco use is ...
Eligibility Criteria
Inclusion
- Lung adenocarcinoma
- Patients diagnosed at a metastatic stage
- Patient who benefited an oncogenic driver research on their histologic samples
- Medical follow-up entirely done in Nancy Central Hospital
Exclusion
- Patients with double histology
- Synchronous cancer
- Patients with surgical care
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT04493827
Start Date
January 1 2011
End Date
December 1 2019
Last Update
July 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Régional Universitaire
Vandœuvre-lès-Nancy, Meurthe Et Moselle, France, 54000